PrEP is not cheap. Once-daily Truvada currently costs about $13,000 per year. While private insurance companies and public insurance programs cover these drugs for HIV treatment, the FDA approval of Truvada for PrEP has implications for insurance coverage and public health programs. Some health insurance companies cover PrEP. We also hope that public insurance programs such as Medicaid and Medicare will cover PrEP, but this is not certain and will vary from state to state. At a time of continued economic uncertainty, this is something that public policy advocates will have to tackle in the coming months and years.
Gilead Sciences, the maker of Truvada, has established a Truvada for PrEP Medication Assistance Program to help people without health insurance or other coverage obtain access to Truvada. To find out if you are eligible for this medication assistance program, call 1-855-330-5479.
Gilead will also provide vouchers for free HIV testing and condoms, an opt-in service for regular reminders about HIV testing, and subsidized resistance testing for people newly infected while taking Truvada for PrEP.
Finding funds to cover PrEP will likely be a challenge. Developing strategies to provide access to PrEP for those who need it most will be essential.